physicians are sometimes left with patients in whom a definitive diagnosis of myocardial infarction cannot be made by CK-MB measurements, and an alternative test of even greater sensitivity and specificity is needed.
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The contractile and regulative proteins of different muscle types exist as isoforms because of multiple gene expression and possible translational modifications. [13] [14] [15] Troponin T belongs to the proteins of the contractile apparatus that are unique in their primary structure for cardiac muscle. Our investigative group developed an enzyme immunoassay for the cardiac troponin T isoform, which showed a cross-reactivity with troponin T extracted from mixed skeletal muscle of only 1-2%. 16 With this assay, troponin T was found in serum samples of patients with AMI from 3.5 hours to more than 10 days after onset of pain .16 From these data, a higher sensitivity and specificity of troponin T compared with CK-MB measurements Katus et 
can be anticipated. Therefore, the diagnostic efficiency of troponin T measurements was analyzed in patients admitted to a general hospital with suspected AMI and in patients with skeletal and, possibly, additional cardiac muscle damage.
Methods

Troponin TAssay
A more detailed description of the assay development and of methods used for purification of troponin T, antibody selection, and purification has been published. 16 Cardiac troponin T is measured by a newly developed immunometric one-step sandwich assay. In this assay, an affinity-purified, cardiospecific anti-troponin T fraction of polyclonal antibody is immobilized on polyvinylchloride test tubes. Troponin T standards or serum samples and peroxidaselabeled monoclonal anti-troponin T antibody is added to these antibody-coated test tubes. During the incubation period, the troponin T molecule is bound on different epitopes by both the solid-phase polyclonal antibody fraction and by the liquid-phase monoclonal antibody-enzyme complex. After the unbound peroxidase-labeled monoclonal antibodies were removed by washing, the antibody-enzyme complex adhering to the assay tubes corresponds to the amount of troponin T recognized by the polyclonal and monoclonal anti-troponin T antibodies. The amount of enzyme immobilized, as a direct measure of bound troponin T, is quantified in the spectrophotometer as peroxidase substrate conversion at a wavelength of 405 nm.
Protocol of Troponin TAssay
The assay is manufactured as a test kit consisting of seven components: antibody-coated test tubes, monoclonal antibody-enzyme complex, incubation buffer, troponin T standard, control sera, substrate buffer, and the diammonium salt of 2.2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS). For troponin T measurements, the antibody-enzyme complex, troponin T standards, and ABTS substrate are dissolved in the buffer solution provided in the test kit and thoroughly mixed by vortex. Troponin T standard or unknown patient serum (200 ,u1 ) is manually added to the test tubes while 1 ml antibodyenzyme complex (45 IU) and all the remaining solutions are added by a batch enzyme-linked immunosorbent assay analyzer (Enzymun-testsystem ES Myocardial infarction was excluded if the reported pain was not typical for angina and the 12-lead electrocardiogram remained unaltered. In this group of patients, cardiac enzymes did not reveal the pattern and time-dependent activity changes in serum typical of myocardial cell necrosis.
Patients
All patients gave written, informed consent to participate in the study after thorough explanation of the protocol. The study protocol was approved by the Ethics Committee of the University of Heidelberg. Patients were excluded from the present study who were admitted to the hospital later than 12 hours after the onset of pain or who had valvular heart disease, cardiomyopathy, or left bundle branch block.
The diagnostic value of troponin T measurements was analyzed in two groups of patients ( Table 1) . The first group consisted of 387 consecutive patients admitted to the hospital with suspected AMI. In 131 of these 387 patients, no evidence was found for myocardial cell necrosis on the 12-lead electrocardiogram or by sequential analysis of serum enzymes, and the complaints of the patients were not characteristic of anginal pain. In these 131 patients, the most frequent clinical diagnoses were: bone or joint disease in 49, gastrointestinal disease in 26, cancer in 15, and ethanol intoxication in nine.
Seventy-nine patients complained of unstable angina with the clinical classes being IIIA in two, IIIB in 23, IIIC in two, IIB in five, and IB in 23.19 In these patients, coronary angiography was performed on day 6+2.7 and revealed a significant obstruction (.75% narrowing in vessel diameter) of a major coronary artery in 66 patients (84%). In two patients with symptoms of "unstable angina" but with normal coronary arteries, the clinical diagnosis was perimyocarditis. Acute interventions (bypass surgery or percutaneous transluminal coronary angioplasty) were performed in 29 patients during the initial hospital stay, whereas 25 patients were operated on electively. Six of the patients with unstable angina developed AMI during their hospital stay, of whom one died.
In 21 of the 56 patients with non-Q wave AMI and in 63 of the 121 patients with Q wave AMI who were admitted to the hospital earlier than 5 hours after onset of pain and who agreed to the planned therapeutic and diagnostic procedures, recanalization of an occluded coronary artery was attempted. Recan- Figure 1 shows the distribution of the peak troponin T levels during the first day after hospital admission in 387 patients with chest pain and suspected AMI. Troponin T levels are expressed as a relative troponin T increase, which is defined as the ratio of the patient's troponin T blood level to the analytical sensitivity of the troponin T test (0.5 ,ug/l). With the analytical sensitivity of the troponin T test as a discriminator between normal and elevated values, troponin T was found in 48 of the 210 patients in whom AMI was excluded (11 patients with atypical chest pain and 37 patients with unstable angina; specificity, 78%; Table 2 and Figure 1 ) and in all patients with AMI (sensitivity, 100%), which resulted in a diagnostic efficiency of 88%. Because of the persistent elevation of troponin T serum concentrations, sensitivity of troponin T measurements for detection of AMI remained at 100% until the sixth hospital day. At that time, release of troponin T was still detectable in 15 of the 37 patients (41%) with symptoms of unstable angina and elevated troponin T levels on day 1. Four of these 15 patients with persistently elevated troponin T levels and unstable angina had progressed to AMI as indicated by the electrocardiogram and cardiac enzyme measurements. Specificity and efficiency of the troponin T test on the first day after hospital admission improved to 93% and 95%, respectively, with only (Table 3) , specificity of the troponin T was 95% or 97%, respectively, depending on the discriminator value of 0.5 or 1 ,ug/l troponin T, and sensitivity was 100% or 99%, respectively. In this group, the diagnostic efficiency of troponin T measurements was 98% or 99%, respectively, whereas the efficiency of CK and CK-MB was 87% and 97%, respectively. Time-Dependent Diagnostic Sensitivity of Troponin T Measurements Figure 2 shows the median and interquartile range of troponin T and cardiac enzymes in 121 patients with Q wave AMI. The test results are expressed as ratios of the patients' serum activities to the upper limit of normal in the case of CK and LDH or to the analytical sensitivity of the assay (0.5 ,gg/l) in the case of troponin T. Troponin T appears in circulation slightly earlier than CK activity, and it increases to a first peak value of 40 times the detection limit during the first day. By contrast to CK levels, troponin T levels remain elevated until 12 days or more after onset of pain, revealing a second peak value of 30 times the detection limit on about the fourth day. Serum CK and LDH activity only increase to nine and three times the upper limit of normal, respectively. The prolonged serum elevation of troponin T results in a diagnostic window of 10.5-140 hours after onset of pain, during which troponin T was detectable in all serum samples of all patients (Table 4) . This time interval of absolute diagnostic sensitivity of troponin T measurements is six times that of CK and nearly twice that of LDH.
The changes of troponin T serum concentrations in patients with non-Q wave AMI reveal kinetics similar to those in patients with Q wave AMI (Figure 3 ). Again, a persistent increase of troponin T serum concentrations is found, with a poorly defined peak value on about the fourth day after onset of pain. The time interval of absolute diagnostic sensitivity of troponin T measurements was 10-131 hours after onset of pain (Table 4) . Serum LDH levels were not elevated in all patients with Q wave AMI; thus, for this enzyme, absolute diagnostic sensitivity is not attained. Figure 4 shows the changes in serum concentrations in the 37 of the 66 patients with unstable angina, coronary artery disease, and elevated levels of troponin T. Because in this group there were several episodes of anginal pain of different intensity at various times before and after admission, the changes in serum concentrations are related to the time of admission. In these patients with unstable angina and elevated levels of troponin T, a median increase of troponin T to twice the analytical sensitivity of the test is found on days 1 and 2. Median FIGURE 2. Plot of median and 25th-75th percentile range of relative increase of serum creatine kinase (CK) and lactate dehydrogenase (LDH) activity and troponin T (TnT) concentrations in 121 patients with Q wave acute myocardial infarction (AMI). Relative increase ofmarkerprotein in serum corresponds to the ratio ofpatients' serum activity to the upper limit ofnormal for CK and LDH and the ratio ofpatients' serum concentration to the analytical sensitivity of the test for troponin T.
troponin T levels remain elevated until the sixth hospital day, whereas median serum CK and LDH activities are not elevated.
Validity of Troponin T Measurements in Patients With
Unstable Angina
Troponin T levels were elevated from 0.55 to 3.1 ,ug/l in at least one blood sample in 37 of the 66 patients with unstable angina and with 75% or more obstruction of a major coronary artery and in two of the 13 patients with symptoms of unstable angina but with 75% or less obstruction of a major coronary artery. These latter two patients suffered from acute perimyocarditis. Thus, elevated levels of troponin T were found only in patients with cardiac disease, for example, severe coronary artery narrowing or perimyocarditis (specificity, 100%). Yet in 31 of the 66 patients with symptoms of unstable angina and severe coronary artery disease, circulating troponin T was not found. Thus, in patients with less-severe ischemia, troponin T measurements may not be an effective diagnostic tool. As a consequence, the troponin T test cannot be used to screen for the presence of severe coronary artery disease (predictive value of a negative test, 0.26 and 0.2) ( Table 5) . On the other hand, when elevated levels of troponin T are found, the test indicates severe coronary artery narrowing with high specificity (85% and 95%) ( Table 5) .
Release of troponin T was more frequent in patients with signs of myocardial ischemia on the 12-lead electrocardiogram ( Figure 5 and Table 5 ). In 27 of the 49 patients (55%) with reversible ST segment changes or T wave inversion, or both, circulating troponin T was found, whereas troponin T was detectable in only 10 of 30 patients (33%) with normal electrocardiograms. The correlation between troponin T release and signs of ischemia on the electrocardiogram was improved when only ST segment depression was used as an indicator of ischemia (p <0.005).
In five of six patients with unstable angina who developed AMI during their hospital stay, elevated levels of troponin T were found at least 12 Figure 6 ). CK-MB activity was higher than 10 IU/I in 37 of the 73 patients (51%), whereas the CK-MB/CK ratio was greater than 6% in 11 (15%). Cardiac troponin T was found in 11 patients (15%) and was greater than 1 gg/l in six (8%).
In 28 patients with skeletal and cardiac muscle damage, the serum CK activity was 380-14,000 IU/I. In this group, serum CK-MB activity was elevated in all patients (range, 10-440 IU/l). The ratio of CK-MB/CK activity was less than 6% in 23 of 28 patients despite clear evidence of myocardial cell necrosis in all patients. Troponin T serum concentrations were elevated in all patients to at least twice the detection limit of the assay.
As shown in Table 6 , CK-MB measurements in these patients allow the detection of myocardial cell necrosis with high sensitivity (100%) but with a low specificity (49%). The specificity of CK-MB measurements can be improved greatly by relating the CK-MB activity to total CK. Yet, relating CK-MB to total CK activity is of little clinical value because of its low sensitivity. Troponin T measurements were the most useful test to assess presence or absence of cardiac injury in these patients (sensitivity, 100%; specificity, 84%; efficiency, 89%). The The large increase in troponin T serum concentrations above the detection limit of the assay and the persistent elevation of these concentrations after onset of pain results in a high sensitivity of this test for AMI. In patients with AMI undergoing reperfusion, serum concentrations may exceed 400 times the discriminating serum value, whereas CK and LDH activity generally do not increase more than 60-and 10-fold, respectively. The high relative increase of troponin T concentration in serum was also observed in patients with non-Q wave infarction in whom troponin T levels increased from more than twofold to 37-fold above the detection limit of the assay, whereas CK and CK-MB increased continuously from normal values to no more than ninefold the upper limit of normal. was further improved to 95% without loss in sensitivity when a discriminator of troponin T of 1 j.g/l was used. The diagnostic efficiency of troponin T measurements was 94%. The high specificity of troponin T measurements is also evident in a patient (A, Figure 6 ) with major skeletal muscle damage and CK and CK-MB serum activities of 660 and 18 times the upper limit of normal. In this patient, troponin T levels were just above the analytical sensitivity of the assay. These data show that the cross-reactivity of 1-2% measured with purified skeletal troponin T may not be a relevant problem in clinical practice.
Minor increases in troponin T levels were found, however, in 15% of the patients who were classified as having skeletal muscle damage. In 8% of these patients, troponin T levels exceeded 1 gg/l. The difficulties in excluding additional cardiac muscle damage in these patients can be exemplified in a patient with the diagnosis of rhabdomyolysis after gastroenteritis in whom 5 ,ug/l troponin T was found (A, Figure 6 ). The CK-and CK-MB activity measurements in this patient of 255 and 740 times, respectively, the upper limit of normal and the relatively high CK-MB/CK ratio of 3.9% indicates that, most probably, additional cardiac muscle damage not detected on the electrocardiogram was present in this patient. Thus, although false-positive results of the troponin T test may occur, the coexistence of major skeletal and minor cardiac muscle damage may be a more frequent cause of elevated levels of troponin T. The enhanced sensitivity of troponin T measurements, compared with the CK-MB/CK ratio, was particularly evident in this subgroup of patients with cardiac and skeletal muscle damage.
In summary, the determination of troponin T, compared with conventionally applied analysis of cardiac enzymes, offers several distinct advantages for the diagnosis of AMI: Troponin T is normally not detectable in serum; it is a cardiospecific antigen; and as a subcellularly compartmented protein, its release in serum lasts long after AMI. As shown, the characteristics of this marker protein lead to improved efficiency of serological testing of AMI. In particular, this results in improved detection of minor myocardial cell necrosis and myocardial damage in patients with skeletal muscle damage and results in a larger diagnostic window that allows serological detection of subacute myocardial infarction.
